Compare Charles River Laboratories Intl. Inc (CRL) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Delta Air Lines, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B), while Delta Air Lines, Inc. trades at $90.41 (market cap $58.67B). The key difference: Delta Air Lines, Inc. is far larger — about 4.4× Charles River Laboratories Intl. Inc's market cap, and Delta Air Lines, Inc. pays a 0.87% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | DAL | |
|---|---|---|
Market Cap | $13.22B | $58.67B |
Sector | Health | Industrials |
52-Week High | $282.00 | $93.66 |
52-Week Low | $145.57 | $55.65 |
Enterprise Value | $16.06B | $73.99B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.
CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.
Delta Air Lines (DAL) trades at $91.34, down 0.7% today, amid a bullish technical trend and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.19. Valuation metrics like a P/E of 15.15 and P/S of 0.88 suggest potential undervaluation, while cash flow trends improved to a net positive $1.08B in 2025. Recent news highlights insider sales but also strong Q2 results and industry tailwinds.
Outlook remains positive with an 81.82% analyst buy rating and consensus price target of $108.27, implying ~18% upside. Key risks include fuel cost volatility and competitive pressures, but DAL's premium travel demand and loyalty program strength support growth. Investors should weigh solid fundamentals against macroeconomic sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
